
Supplementary Figure 1. Mean prescribed SCS dosage before and after the index date



Error bars in the figure represent SD. *Q* quartile, *SCS* systemic corticosteroids, *SD* standard deviation Supplementary Table 1. Asthma severity and control status before and after the index date

		Severity and control status after the index date					
		Severe asthma			Mild to moderate asthma		
		Total	Uncontrolled	Controlled	Total	Uncontrolled	Controlled
Severity and control status before the index date		n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
Severe asthma	<i>N</i> = 581ª	453 (78.0)	151 (26.0)	302 (52.0)	128 (22.0)	28 (4.8)	100 (17.2)
Uncontrolled	<i>N</i> = 193ª	154 (79.8)	118 (61.1)	36 (18.7)	39 (20.2)	23 (11.9)	16 (8.3)
Controlled	<i>N</i> = 388ª	299 (77.1)	33 (8.5)	266 (68.6)	89 (22.9)	5 (1.3)	84 (21.6)
Mild to moderate asthma	<i>N</i> = 6,190 ^a	326 (5.3)	76 (1.2)	250 (4.0)	5,864 (94.7)	976 (15.8)	4,888 (79.0)
Uncontrolled	<i>N</i> = 1,118 ^a	88 (7.9)	55 (4.9)	33 (3.0)	1,030 (92.1)	728 (65.1)	302 (27.0)
Controlled	<i>N</i> = 5,072 ^a	238 (4.7)	21 (0.4)	217 (4.3)	4,834 (95.3)	248 (4.9)	4,586 (90.4)

^aThe analysis of asthma control and severity was conducted only in cases where the multifaceted decision criteria according to the definitions in the European Respiratory Society/American Thoracic Society guidelines were definitively verified.

Supplementary Table 2. Exacerbation-related events

	Non-SCS	Q1	Q2	Q3	Q4
	<i>N</i> = 7,476	<i>N</i> = 749	N = 802	N = 775	N = 777
Hospitalization					
Mean (SD), days/year	0.78 (11.41)	0.37 (3.08)	0.63 (4.16)	1.21 (15.16)	4.58 (25.89)
Unadjusted rate ratio (95% CI)	Reference	0.475	0.802	1.545	5.844
		(0.191–1.181)	(0.333–1.930)	(0.636–3.749)	(2.392–14.273)
Adjusted rate ratio (95% CI)	Reference	0.483	0.795	1.582	5.784
		(0.193–1.209)	(0.329–1.921)	(0.648–3.861)	(2.355–14.207)
ntermittent SCS prescriptions					
Mean (SD), times/year	0.10 (0.55)	1.04 (4.04)	0.73 (2.98)	1.60 (13.30)	1.77 (3.25)
Jnadjusted rate ratio (95% CI)	Reference	10.308	7.300	15.923	17.632
		(8.389–12.665)	(5.946-8.961)	(13.051–19.427)	(14.466–21.492)
Adjusted rate ratio (95% CI)	Reference	10.518	7.235	16.075	17.127
,		(8.556–12.929)	(5.888–8.889)	(13.152–19.646)	(14.054–20.873)

Cl confidence interval, SCS systemic corticosteroids, SD standard deviation, Q quartile

Supplementary Table 3. Corticosteroid-related comorbidities

	Non-SCS	Q1	Q2	Q3	Q4
	<i>N</i> = 7,476	<i>N</i> = 749	N = 802	N = 775	N = 777
Dyslipidaemia					
n (%)	1,778 (23.8)	152 (20.3)	176 (21.9)	151 (19.5)	219 (28.2)
Unadjusted odds ratio (95% CI)	Reference	0.816	0.901	0.776	1.258
,		(0.678–0.983)	(0.756-1.074)	(0.644–0.934)	(1.066–1.484)
Adjusted odds ratio (95% CI)	Reference	0.883	0.933	0.774	1.106
		(0.725–1.074)	(0.775–1.123)	(0.636–0.941)	(0.928–1.318)
Hypertension		(0.120 1.01 1)	(0.170 1.120)	(0.000 0.011)	(0.020 1.010)
n (%)	1,653 (22.1)	138 (18.4)	152 (19.0)	154 (19.9)	195 (25.1)
	Reference	0.796	0.824	0.874	1.180
Unadjusted odds ratio (95% CI)	Relefence				
A division of the metric $(0E^{0}/C^{1})$	Deference	(0.656–0.965)	(0.685–0.991)	(0.726–1.051)	(0.995–1.401)
Adjusted odds ratio (95% CI)	Reference	0.887	0.865	0.901	1.014
		(0.719–1.094)	(0.708–1.057)	(0.737–1.103)	(0.842–1.223)
Osteoporosis			/>	/	
n (%)	169 (2.3)	17 (2.3)	23 (2.9)	26 (3.4)	169 (21.8)
Unadjusted odds ratio (95% CI)	Reference	1.004	1.277	1.501	12.018
		(0.606–1.663)	(0.821–1.986)	(0.986–2.284)	(9.561–15.106)
Adjusted odds ratio (95% CI)	Reference	1.025	1.201	1.389	11.787
		(0.614–1.711)	(0.766-1.884)	(0.905–2.132)	(9.249–15.021)
Diabetes		,	, ,	, , , , , , , , , , , , , , , , , , ,	,
n (%)	852 (11.4)	75 (10.0)	114 (14.2)	91 (11.7)	154 (19.8)
Unadjusted odds ratio (95% CI)	Reference	0.865	1.288	1.034	1.922
		(0.674–1.110)	(1.044–1.590)	(0.822–1.302)	(1.589–2.325)
Adjusted odds ratio (95% CI)	Reference	0.948	1.384	1.073	1.771
	Reference	(0.734–1.225)	(1.112–1.722)	(0.846–1.361)	(1.453–2.159)
Apviet/Neurosia		(0.754–1.225)	(1.112 - 1.722)	(0.040-1.501)	(1.435–2.159)
Anxiety/Neurosis	F22 (7 1)	72 (0,6)	70 (9 7)	96 (11 1)	00 (10 C)
n(%)	533 (7.1)	72 (9.6)	70 (8.7)	86 (11.1)	82 (10.6)
Unadjusted odds ratio (95% CI)	Reference	1.385	1.246	1.626	1.537
	_ /	(1.070–1.794)	(0.960–1.616)	(1.278–2.069)	(1.203–1.964)
Adjusted odds ratio (95% CI)	Reference	1.317	1.155	1.506	1.433
		(1.015–1.709)	(0.889–1.502)	(1.181–1.919)	(1.119–1.835)
Depression					
n (%)	368 (4.9)	32 (4.3)	44 (5.5)	58 (7.5)	64 (8.2)
Unadjusted odds ratio (95% CI)	Reference	0.862	1.121	1.562	1.734
		(0.596–1.247)	(0.813–1.546)	(1.172–2.083)	(1.315–2.286)
Adjusted odds ratio (95% CI)	Reference	0.828	1.073	1.496	1.708
,		(0.572–1.199)	(0.777–1.481)	(1.121–1.996)	(1.294–2.255)

Cl confidence interval, SCS systemic corticosteroids, Q quartile

Supplementary Table 4. Total medical costs

	Non-SCS	Q1	Q2	Q3	Q4
	<i>N</i> = 7,476	<i>N</i> = 749	N = 802	N = 775	N = 777
Total medical costs	·				
Mean, USD/year (95% CI)	3,224	3,403	3,968	3,871	7,847
	(3,017–3,431)	(2,744–4,061)	(3,333–4,603)	(3,228–4,514)	(7,197–8,497)
Unadjusted difference,	Reference	179	744	647	4,623
USD/year (95% CI)		(-512–869)	(77–1,412)	(-29–1,323)	(3,941–5,305)
Adjusted difference, USD/year (95% CI)	Reference	259 (-429–947)	774 (108–1,439)	655 (-18–1,329)	4,439 (3,759–5,119)

CI confidence interval, SCS systemic corticosteroids, Q quartile, USD United States dollars

	Non-SCS	Q1	Q2	Q3	Q4
	N = 7,476	N = 749	N = 802	N = 775	N = 777
Asthma drug	F7 4	64.0	707	007	1 0 1 1
Mean, USD/year (95% CI)	571	618	737	837	1,244
	(554–588)	(564–672)	(685–789)	(783–890)	(1,190–1,297)
Jnadjusted difference, USD/year (95% CI)	Reference	48 (-9–104)	166 (111–221)	266 (210–322)	673 (617–729)
		(-9-104) 50	166	(210-322) 264	661
Adjusted difference, USD/year (95% CI)	Reference	(-7–107)	(111–221)	(208–320)	(605–717)
Asthma drug (except SCS)		(/ 10/)	(111 221)	(200 020)	
	570	615	733	827	1,203
Mean, USD/year (95% CI)	(553–587)	(561–669)	(681–785)	(774–880)	(1,150–1,256)
Inadjusted difference USD/veer (05% CI)	, ,	4 6	` 164 ´	257	633
Jnadjusted difference, USD/year (95% CI)	Reference	(-11-102)	(109–218)	(202–313)	(577–689)
Adjusted difference, USD/year (95% CI)	Reference	48	163	255	622
	Reference	(-9–105)	(108–218)	(200–311)	(565–678)
Hypertension drug					
Mean, USD/year (95% CI)	61	51	54	59	66
, - · , ()	(57–65)	(37–64)	(41–67)	(46–72)	(53–79)
Jnadjusted difference, USD/year (95% CI)	Reference	-10	-7	-2	5
		(-24-3) -4	(-20-6) -3	(-15–12) 2	(-9–19) –1
Adjusted difference, USD/year (95% CI)	Reference	-4 (-17–9)	(-16-10)	(-11-15)	(-14–12)
Dyslipidaemia drug		(11-3)	(10-10)	(11-13)	(14-12)
	38	34	31	28	55
Mean, USD/year (95% CI)	(35–40)	(25–43)	(23–40)	(20–37)	(46–64)
In a division of differences and LICD (see an (OEC) (C))	, , , , , , , , , , , , , , , , , , ,	-4	-6	-9	17
Jnadjusted difference, USD/year (95% CI)	Reference	(-13-5)	(-16-3)	(-18-0)	(8–27)
Adjusted difference, USD/year (95% CI)	Reference	-1	-5	-9	`13 <i>´</i>
	Relefence	(-11-8)	(-14-4)	(-18–0)	(3–22)
Diabetes drug					
Mean, USD/year (95% CI)	36	34	35	29	42
	(32–41)	(19–48)	(21–50)	(15–44)	(27–56)
Jnadjusted difference, USD/year (95% CI)	Reference	-2	-1	-7	6
,		(-18–13)	(-16–14)	(-22-8)	(-10-21)
Adjusted difference, USD/year (95% CI)	Reference	1 (−15–16)	1 (−13–16)	-5 (-20–10)	2 (-13–18)

Cl confidence interval, SCS systemic corticosteroids, Q quartile, USD United States dollars

Supplementary Table 6. Definition of asthma severity and control status

Category	ERS/ATS criteria	Items used for criteria of control in this study (by using data available in the database)		
		Use of ERS/ATS criteria without alteration	Conversion from ERS/ATS criteria	
	GINA ⁴ Step 4–5	×	Prescribed high-dosage ICS plus at least one other controller	
Severe asthma	Use of systemic corticosteroids ≥50%	Number of days of prescriptions for systemic corticosteroids ≥183	_	
	ACQ >1.5 ACT <20	×	Number of SABA prescription records (≥208 attacks)ª	
Severe, uncontrolled asthma	Short-term use of systemic corticosteroids ≥2 times (>3 times each)	×	At least two prescription records for short-term use of systemic corticosteroids or injectable corticosteroids ^b	
	Hospitalization admission to ICU mechanical ventilation ≥1 time	Number of hospitalizations for asthma ^c (emergency visits cannot be used)	_	
	Airflow limitation	×	×	

ERS/ATS European Respiratory Society and American Thoracic Society, *ICU* intensive care unit, *ICS* inhaled corticosteroids, *LABA* long-acting β_2 -agonist, *SABA* short-acting β_2 -agonist, *OCS* oral corticosteroids, *GINA* Global Initiative for Asthma, *ACQ* Asthma Control Questionnaire, *ACT* Asthma control test

^aRefers to a description of one criterion of level of asthma symptom control in GINA 2017 – "Reliever needed more than twice/week (in the past 4 weeks)" – and considering real-world usage of SABA as 50% of each formulation. The number of inhalations per attack depends on the formulation.

^bRefers to patients with at least two prescription records for short-term use of systemic corticosteroids or injectable corticosteroids ≤12 months prior to the index date. However, a minimum 14-day interval between the relevant record and the previous record was required.

^cWith at least one prescription of injectable corticosteroids.

×: data in the database could not be used as originally recorded. In these cases, criteria were altered so that data compiled in the database could be used (shown in the right column).

-: conversion of criteria was not necessary because data from the database could be used as originally recorded.

Note that the criterion for airflow limitation could not be appropriately converted and therefore was not used in this study.